NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Forecast, Price & News

$1.91

-0.91 (-32.27%)

(As of 06/9/2023 ET)

Compare

Today's Range: $1.50
▼
$2.07
50-Day Range: $1.71
▼
$5.06
52-Week Range: $0.72
▼
$5.89

Volume: 7.89 million shs
Average Volume: 4.29 million shs
Market Capitalization: $46.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.38

Elevation Oncology MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 181.4% Upside
$5.38 Price Target
Short Interest: Healthy
2.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.60
Based on 13 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.30) to ($1.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

150th out of 988 stocks

Biological Products, Except Diagnostic Industry

22nd out of 158 stocks

3.3

Analyst's Opinion

Consensus Rating
Elevation Oncology has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.38, Elevation Oncology has a forecasted upside of 181.4% from its current price of $1.91.
Amount of Analyst Coverage
Elevation Oncology has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.29% of the float of Elevation Oncology has been sold short.
Short Interest Ratio / Days to Cover
Elevation Oncology has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Elevation Oncology has recently decreased by 64.17%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Elevation Oncology does not currently pay a dividend.
Dividend Growth
Elevation Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELEV.

2.0

News and Social Media Coverage

News Sentiment
Elevation Oncology has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Elevation Oncology this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Elevation Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.00% of the stock of Elevation Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.01% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Elevation Oncology are expected to grow in the coming year, from ($1.30) to ($1.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Elevation Oncology is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Elevation Oncology is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Elevation Oncology has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Elevation Oncology (NASDAQ:ELEV) Stock

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Stock News Headlines

May 30, 2023 | marketbeat.com

Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology

Shares of ELEV have risen 428% YTD. Will the stock continue to perform with a critical upcoming catalyst on the horizon?

June 9, 2023 | benzinga.com

Elevation Oncology shares are trading lower after the company announced a $50 million public offering.

June 10, 2023 | Behind the Markets (Ad)

Avoid the upcoming bloodbath

By this time next year, millions of retirees are going to be so broke they'll struggle to keep the heat running, and may have to make hard decisions about which medications they can afford. It's all because of an upcoming government announcement that could make last year's record breaking 7% inflation look like nothing. Get the details that could keep your money safe here >>>

June 9, 2023 | marketwatch.com

Elevation Oncology Shares Tumble Premarket After Stock Offering >ELEV

June 9, 2023 | msn.com

Elevation Oncology Plummets on $50M Public Offering

June 9, 2023 | investorplace.com

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

June 9, 2023 | seekingalpha.com

Elevation Oncology slumps 25%, prices $50M public offering

June 9, 2023 | msn.com

Elevation Oncology slumps 25% on $50M public offering pricing

June 10, 2023 | Behind the Markets (Ad)

Avoid the upcoming bloodbath

June 9, 2023 | finance.yahoo.com

Elevation Oncology Announces Pricing of $50 Million Public Offering

June 8, 2023 | marketwatch.com

Elevation Oncology Shares Fall After Proposed Public Offering

June 8, 2023 | finance.yahoo.com

Elevation Oncology Announces Launch of Proposed Public Offering

June 7, 2023 | americanbankingnews.com

Head-To-Head Comparison: Exscientia (NASDAQ:EXAI) vs. Elevation Oncology (NASDAQ:ELEV)

June 6, 2023 | msn.com

Wedbush Maintains Elevation Oncology (ELEV) Outperform Recommendation

June 3, 2023 | finance.yahoo.com

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

June 1, 2023 | americanbankingnews.com

Elevation Oncology (NASDAQ:ELEV) Stock Rating Upgraded by SVB Securities

May 31, 2023 | americanbankingnews.com

Elevation Oncology (NASDAQ:ELEV) Upgraded by SVB Leerink to Outperform

May 28, 2023 | americanbankingnews.com

Elevation Oncology (NASDAQ:ELEV) and Freeline Therapeutics (NASDAQ:FRLN) Financial Comparison

May 26, 2023 | seekingalpha.com

Elevation Oncology up 61% on early-stage data for gastric cancer treatment

May 26, 2023 | msn.com

Elevation Oncology Blasts Higher on New Cancer Treatment

May 26, 2023 | fool.com

Elevation Oncology (NASDAQ: ELEV)

May 26, 2023 | investorplace.com

Why Is Elevation Oncology (ELEV) Stock Up 57% Today?

May 20, 2023 | americanbankingnews.com

SVB Leerink Weighs in on Elevation Oncology, Inc.'s Q2 2023 Earnings (NASDAQ:ELEV)

May 20, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Elevation Oncology, Inc. Lifted by Analyst (NASDAQ:ELEV)

May 19, 2023 | finance.yahoo.com

Private equity firms among Elevation Oncology, Inc.'s (NASDAQ:ELEV) largest shareholders, saw gain in holdings value after stock jumped 34% last week

May 15, 2023 | finance.yahoo.com

Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements

April 26, 2023 | finance.yahoo.com

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

See More Headlines

ELEV Price History

30 days | 90 days | 365 days | Advanced Chart

ELEV Company Calendar

Last Earnings: 5/15/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELEV
CUSIP: N/A
CIK: 1783032
Web: www.elevationoncology.com
Phone: 716-371-1125
Fax: N/A
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.38
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +181.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -260.48%
Return on Assets: -163.21%

Debt

Debt-to-Equity Ratio: 0.88
Current Ratio: 5.60
Quick Ratio: 5.60

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.10 per share
Price / Book: 0.91

Miscellaneous

Outstanding Shares: 24,340,000
Free Float: 20,201,000
Market Cap: $46.49 million
Optionable: Not Optionable
Beta: 0.90

Key Executives

Dr. David Dornan Ph.D. (Age 45)
Chief Scientific Officer
Comp: $545.5k

Dr. Shawn M. Leland Pharm.D. (Age 38)
R.Ph., Advisor
Comp: $881.58k

Ms. Valerie Malyvanh Jansen M.D. (Age 45)
Ph.D., Chief Medical Officer
Comp: $641.53k

Mr. Joseph J. Ferra Jr. (Age 48)
CFO, Interim CEO & Pres

Ms. Tammy Furlong CPA
P.M.P., VP of Fin. & Accounting and Sec.

Candice Masse
Sr. Director of Corp. Communications & Investor Relations

Mr. Robert C. Yang
VP of Legal Affairs

Mr. Ryan Bloomer
Head of CMC

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELEV Stock - Frequently Asked Questions

Should I buy or sell Elevation Oncology stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELEV shares.
View ELEV analyst ratings or view top-rated stocks.
What is Elevation Oncology's stock price forecast for 2023?: 5 analysts have issued twelve-month price objectives for Elevation Oncology's stock. Their ELEV share price forecasts range from $2.00 to $8.00. On average, they expect the company's stock price to reach $5.38 in the next year. This suggests a possible upside of 181.4% from the stock's current price.
View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts.
How have ELEV shares performed in 2023?: Elevation Oncology's stock was trading at $0.95 on January 1st, 2023. Since then, ELEV shares have increased by 101.1% and is now trading at $1.91.
View the best growth stocks for 2023 here.
When is Elevation Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ELEV earnings forecast.
How were Elevation Oncology's earnings last quarter?: Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01.
When did Elevation Oncology IPO?: (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at a price of $15.00-$17.00 per share.

What is Elevation Oncology's stock symbol?: Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV."
Who are Elevation Oncology's major shareholders?: Elevation Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sio Capital Management LLC (3.69%), Geode Capital Management LLC (0.55%), Two Sigma Investments LP (0.31%), Renaissance Technologies LLC (0.22%), State Street Corp (0.18%) and BlackRock Inc. (0.14%). Insiders that own company stock include Global Hc Fund Pte Vertex II, Global Strategic Fund I Venbio and Yun-Lung Chen.
View institutional ownership trends.
How do I buy shares of Elevation Oncology?: Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Elevation Oncology's stock price today?: One share of ELEV stock can currently be purchased for approximately $1.91.
How much money does Elevation Oncology make?: Elevation Oncology (NASDAQ:ELEV) has a market capitalization of $46.49 million. The company earns $-95,080,000.00 in net income (profit) each year or ($7.34) on an earnings per share basis.
How can I contact Elevation Oncology?: The official website for the company is www.elevationoncology.com. The company can be reached via phone at 716-371-1125 or via email at ir@elevationoncology.com.

This page (NASDAQ:ELEV) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial